Clin Mol Hepatol.
2023 Oct;29(4):844-850. 10.3350/cmh.2023.0291.
Waiting for the changes after the adoption of steatotic liver disease
- Affiliations
-
- 1Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
- 2Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea
- KMID: 2546373
- DOI: http://doi.org/10.3350/cmh.2023.0291
Abstract
- Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term “steatosis” instead of “fatty”. Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
- Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
